Mukherjee, S;
Lord, S;
Harman, R;
McIntosh, D;
Ooms, A;
Parkes, M;
Radhakrishna, G;
... Hawkins, MA; + view all
(2022)
CHARIOT: A phase I dose escalation study combining ATR inhibitor Berzosertib with chemoradiotherapy in oesophageal cancer using time to event continual reassessment (TiTE-CRM) method: Results from A1 cohort (combination with palliative RT).
Presented at: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO).
Preview |
Text
CHARIOT_A1Abstract_ESMO2022_03May2022.pdf - Other Download (184kB) | Preview |
| Type: | Conference item (Presentation) |
|---|---|
| Title: | CHARIOT: A phase I dose escalation study combining ATR inhibitor Berzosertib with chemoradiotherapy in oesophageal cancer using time to event continual reassessment (TiTE-CRM) method: Results from A1 cohort (combination with palliative RT) |
| Event: | Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) |
| Dates: | 9 Sep 2022 - 13 Sep 2022 |
| Open access status: | An open access version is available from UCL Discovery |
| Publisher version: | https://doi.org/10.1016/j.annonc.2022.07.1369 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > UCL BEAMS UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Med Phys and Biomedical Eng |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10162291 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
